AXSM Stock Analysis: Axsome Therapeutics | NASDAQ

Antidepressants, Sleep Disorders, Migraine, Neurology

Total Rating 24

Safety 31

Buy Signal -0.56

Biotechnology
Industry Rotation: +0.6

Market Cap: 7.34B
Avg Turnover: 153M

Risk 3d forecast

Volatility53.3%

VaR 5^th Pctl8.34%

VaR vs Median-4.95%

Reward TTM

Sharpe Ratio0.03

Rel. Str. IBD6.2

Rel. Str. Peer Group16.9 pctl

Character TTM

Beta0.334

Beta Downside0.284

Hurst Exponent0.396

Choppyness21.5%

Drawdowns 3y

Max DD49.13%

CAGR/Max DD0.60

CAGR/Mean DD2.39

EPS (Earnings per Share)

Last SUE: 1.67
Qual. Beats: 1

Revenue

Rev. CAGR: 59.99%
Rev. Trend: 99.4%

Last SUE: 2.13
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Below Sma 200d

Tailwinds

Shakeout

Seasonality 10.8 years of data

Jan -8.4% 12

Feb -4.9% 27

Mar -6.8% 28

Apr +13.1% 25

May +0.2% 2

Jun +3.7% 0

Jul -5.3% 25

Aug +1.0% 15

Sep -1.5% 16

Oct +0.2% 8

Nov +10.6% 31

Dec +7.2% 41

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AXSM Axsome Therapeutics

Axsome Therapeutics is a U.S.-based biopharmaceutical company that develops and commercializes novel therapies for central nervous system (CNS) disorders. The company markets three products: Auvelity for major depressive disorder in adults, Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and Symbravo (AXS-07) for the acute treatment of migraine with or without aura.

In addition to its commercial portfolio, Axsome is advancing a pipeline of CNS candidates, including AXS-05 (in Phase III for Alzheimers disease agitation and Phase II for smoking cessation), AXS-12 (Phase II for narcolepsy), AXS-14 (Phase III for fibromyalgia), and solriamfetol (Phase III for additional indications such as ADHD and shift work disorder). The company also maintains a research collaboration with Duke University to evaluate AXS-05 in smoking cessation.

Axsome is classified within the Health Care sectors Pharmaceuticals sub-industry and operates as a mid-cap specialty biopharmaceutical company listed on NASDAQ since its November 2015 IPO. Its business model centers on in-house drug development targeting underserved CNS indications, complemented by partnered research agreements and a commercial organization that markets its approved therapies in the United States. The company was incorporated in 2012 and is headquartered in New York, New York.

Headlines to Watch Out For

Auvelity sales accelerate driving top-line growth
Sunosi revenue maintains steady narcolepsy market share
Symbravo launch expands acute migraine treatment portfolio
AXS-05 Alzheimers agitation Phase III data readout pending
Pipeline advancement in CNS disorders diversifies long-term revenue
Cash burn and capital raises pressure near-term margins

Piotroski VR-10 (Strict) 3.0

Net Income: -157.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA 5.25 > 1.0
NWC/Revenue: 24.84% < 20% (prev 36.53%; Δ -11.70% < -1%)
CFO/TA -0.10 > 3% & CFO -81.8m > Net Income -157.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.42 > 1.5 & < 3
Outstanding Shares: last quarter (52.4m) vs 12m ago 4.84% < -2%
Gross Margin: 93.25% > 18% (prev 91.86%; Δ 1.38% > 0.5%)
Asset Turnover: 115.7% > 50% (prev 83.86%; Δ 31.81% > 0%)
Interest Coverage Ratio: -27.32 > 6 (EBIT TTM -153.5m / Interest Expense TTM 5.62m)

Altman Z'' -5.18

A: 0.26 (Total Current Assets 724.6m - Total Current Liabilities 509.7m) / Total Assets 826.8m
B: -1.74 (Retained Earnings -1.43b / Total Assets 826.8m)
C: -0.21 (EBIT TTM -153.5m / Avg Total Assets 748.0m)
D: 0.15 (Book Value of Equity 105.4m / Total Liabilities 721.3m)
Altman-Z'' = -5.18 = D

Beneish M -2.62

DSRI: 1.13 (Receivables 343.1m/196.5m, Revenue 865.3m/561.3m)
GMI: 0.99 (GM 91.86% / 93.25%)
AQI: 0.88 (AQ_t 0.10 / AQ_t-1 0.12)
SGI: 1.54 (Revenue 865.3m / 561.3m)
TATA: -0.09 (NI -157.3m - CFO -81.8m) / TA 826.8m)
Beneish M = -2.62 (Cap -4..+1) = A

What is the price of AXSM shares?

As of November 06, 2026, the stock is trading at USD 129.80 with a total of 1,109,346 shares traded. Over the past week, the price has changed by -9.52%, over one month by -26.70%, over three months by -39.02% and over the past year by -4.34%.

Current recommended Stop Loss: 120.10 (which is 7.5% or 1.2 ATR below the current price).

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.77. Therefore, it is recommended to buy AXSM.

StrongBuy: 18
Buy: 3
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the AXSM price?

Analysts Target Price	271.1	108.8%

Axsome Therapeutics (AXSM) - Fundamental Data Overview as of 05 November 2026

Market Cap USD = 7.34b (7.34b USD * 1.0 USD.USD)
P/E Forward = 25.9067
P/S = 8.4832
P/B = 85.5219
Revenue TTM = 865.3m USD
EBIT TTM = -153.5m USD
EBITDA TTM = -144.4m USD
Long Term Debt = 117.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 70.7m USD (from shortTermDebt, last quarter)
Debt = 255.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.7m
Net Debt = -58.5m USD (calculated: Debt 255.4m - CCE 313.9m)
Enterprise Value = 7.28b USD (7.34b + Debt 255.4m - CCE 313.9m)
Interest Coverage Ratio = -27.32 (Ebit TTM -153.5m / Interest Expense TTM 5.62m)
EV/FCF = -88.97x (Enterprise Value 7.28b / FCF TTM -81.8m)
FCF Yield = -1.12% (FCF TTM -81.8m / Enterprise Value 7.28b)
FCF Margin = -9.46% (FCF TTM -81.8m / Revenue TTM 865.3m)
Net Margin = -18.18% (Net Income TTM -157.3m / Revenue TTM 865.3m)
Gross Margin = 93.25% ((Revenue TTM 865.3m - Cost of Revenue TTM 58.4m) / Revenue TTM)
Gross Margin QoQ = 93.14% (prev 93.79%)
Tobins Q-Ratio = 8.81 (Enterprise Value 7.28b / Total Assets 826.8m)
Interest Expense / Debt = 2.20% (Interest Expense 5.62m / Debt 255.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -121.3m (EBIT -153.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.42 (Total Current Assets 724.6m / Total Current Liabilities 509.7m)
Debt / Equity = 2.42 (Debt 255.4m / totalStockholderEquity, last quarter 105.4m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -58.5m / EBITDA -144.4m)
Debt / FCF = 0.71 (negative FCF - burning cash) (Net Debt -58.5m / FCF TTM -81.8m)
Total Stockholder Equity = 82.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.03% (Net Income -157.3m / Total Assets 826.8m)
RoE = -189.7% (Net Income TTM -157.3m / Total Stockholder Equity 82.9m)
RoCE = -76.50% (EBIT -153.5m / Capital Employed (Equity 82.9m + L.T.Debt 117.7m))
RoIC = -35.21% (negative operating profit) (NOPAT -121.3m / Invested Capital 344.5m)
WACC = 6.60% (E(7.34b)/V(7.60b) * Re(6.77%) + D(255.4m)/V(7.60b) * Rd(2.20%) * (1-Tc(0.21)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.61 | Cagr: 4.43%
[DCF] Fair Price = unknown (Cash Flow -81.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.67 | # QB: 1
Revenue Correlation: 99.40 | Revenue CAGR: 59.99% | SUE: 2.13 | # QB: 1
EPS current Quarter (2027-03-31): EPS=0.03 | Chg30d=-81.66% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=-2.60 | Chg30d=+3.36% | Revisions=-70% | GrowthEPS=+25.1% | GrowthRev=+49.4%
EPS next Year (2027-12-31): EPS=4.02 | Chg30d=-14.71% | Revisions=-44% | GrowthEPS=+254.6% | GrowthRev=+52.5%
[Analyst] Revisions Ratio: -59% (up=2, down=12)